title: Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?
authors.affiliation: Acute and Chronic Renal Failure Unit, Department of Clinical and Experimental Medicine, Parma University Medical School, Parma, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Fiaccadori
authors.forename: Umberto
authors.initials: U
authors.lastname: Maggiore
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Regolisti
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000075202:Contraindications; D065427:Factor Xa Inhibitors; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D011134:Polysaccharides / Q000627:therapeutic use*; D006435:Renal Dialysis; D013923:Thromboembolism / Q000139:chemically induced*; D061205:Vascular Calcification / Q000139:chemically induced*; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014859:Warfarin
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011134:Polysaccharides; D014812:Vitamin K; D014859:Warfarin; D000077425:Fondaparinux; D001241:Aspirin